JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Boston Scientific Corp.

Затворен

СекторЗдравеопазване

101.13 -1.24

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

101.02

Максимум

101.42

Ключови измерители

By Trading Economics

Приходи

123M

795M

Продажби

398M

5.1B

P/E

Средно за сектора

59.135

37.461

Марж на печалбата

15.708

Служители

53,000

EBITDA

155M

1.4B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+25.06% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-4.6B

149B

Предишно отваряне

102.37

Предишно затваряне

101.13

Настроения в новините

By Acuity

30%

70%

68 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Boston Scientific Corp. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.10.2025 г., 11:00 ч. UTC

Печалби

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

17.10.2025 г., 11:43 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Rest of Nalu Medical for $533 Million

23.07.2025 г., 11:16 ч. UTC

Печалби

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

22.10.2025 г., 10:32 ч. UTC

Печалби

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22.10.2025 г., 10:32 ч. UTC

Печалби

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22.10.2025 г., 10:31 ч. UTC

Печалби

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22.10.2025 г., 10:31 ч. UTC

Печалби

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22.10.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22.10.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22.10.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 3Q Adj EPS 75c >BSX

22.10.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22.10.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22.10.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 3Q Sales $5.07B >BSX

22.10.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 3Q EPS 51c >BSX

22.10.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific Sees 4Q Adj EPS 77c-Adj EPS 79c >BSX

17.10.2025 г., 11:02 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Make Upfront Cash Payment of About $533 Million for Nalu Equity it Doesn't Already Own >BSX

17.10.2025 г., 11:02 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific: Nalu Acquisition to Expand Neuromodulation Offerings for People Living With Chronic Pain >BSX

17.10.2025 г., 11:01 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific: Nalu Medical Focused on Developing Minimally Invasive Solutions for Chronic Pain >BSX

17.10.2025 г., 11:00 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific Announces Agreement To Acquire Nalu Medical, Inc. >BSX

9.09.2025 г., 12:58 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Elutia's Bioenvelope Business for $88M

9.09.2025 г., 12:31 ч. UTC

Придобивния, сливания и поглъщания

Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88M

23.07.2025 г., 10:32 ч. UTC

Печалби

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

23.07.2025 г., 10:31 ч. UTC

Печалби

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

23.07.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

23.07.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

23.07.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 2Q EPS 53c >BSX

23.07.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 2Q Sales $5.06B >BSX

23.07.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

23.07.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 2Q Adj EPS 75c >BSX

23.07.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

Сравнение с други в отрасъла

Ценова промяна

Boston Scientific Corp. Прогноза

Ценова цел

By TipRanks

25.06% нагоре

12-месечна прогноза

Среден 126.45 USD  25.06%

Висок 140 USD

Нисък 113 USD

Според 24 анализатори от Wall Street, предложили 12-месечна ценова цел за Boston Scientific Corp. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

24 ratings

23

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

102.95 / 104.93Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

68 / 371 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat